Barclays cuts Ventas stock target to USD 91 ahead of third-quarter results

Published on 10/15/2026 at 13:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 1.73 billion, up 21.70 percent year over year. Ventas stock trades at EUR 75.49 on October 15, 2026.

Analyst view and upcoming dates

Barclays cut its Ventas target from USD 102.00 to USD 91.00 on October 13, 2026.
Second-quarter revenue reached USD 1.73 billion, up 21.70 percent year over year.
Ventas stock trades at EUR 75.49 at 1:35 p.m. CEST at Lang & Schwarz on October 15, 2026.
Ventas is scheduled to report third-quarter results on October 27, 2026.

Geometrisches Bauhaus-Poster mit bunten Formen und dem Schriftzug HEALTHCARE — Ventas Inc. (US92276F1003) zählt zum Gesundheitssektor, Bauhaus-Poster kombiniert geometrische Formen mit Schriftzug HEALTHCARE, Illustration mit AI erstellt.

Ventas Inc. (ISIN US92276F1003) was trading at EUR 75.49 at Lang & Schwarz on October 15, 2026 at 1:35 p.m. CEST. On October 13, 2026, Barclays lowered its price target for Ventas from USD 102.00 to USD 91.00 while keeping an Equal Weight rating, as Markets Insider reported. The revision came in a third-quarter earnings preview.

Revenue growth sets the backdrop

Ventas reported USD 1.73 billion in revenue for the second quarter of 2026, up 21.70 percent from the prior-year quarter. Adjusted earnings per share reached USD 0.97 against a USD 0.96 consensus estimate, according to MarketBeat. The figures give the upcoming report a clear benchmark, particularly because the company operates a large healthcare and senior housing portfolio.

Three dated signals for Ventas

On July 29, 2026, Ventas reported USD 1.73 billion in quarterly revenue and adjusted earnings per share of USD 0.97, according to MarketBeat. On September 30, 2026, the quarterly dividend of USD 0.52 per share went ex-dividend, according to the same MarketBeat report. On October 13, 2026, Barclays cut its target from USD 102.00 to USD 91.00, leaving the Equal Weight rating unchanged, as Markets Insider reported.

What does the target cut change?

The lower target puts more weight on execution ahead of the next report. Ventas had a USD 84.31 NYSE quote after the October 14, 2026 session, while the Barclays target remained USD 91.00, a 7.93 percent premium to that primary-exchange price. The company says its platform spans senior housing, healthcare properties and research facilities, with approximately 1,450 properties as of June 30, 2026, according to Ventas.

Next report arrives October 27

MarketBeat lists October 27, 2026 as Ventas's next third-quarter reporting date after the market closes, with the conference call scheduled for 10:00 a.m. ET. The consensus calls for revenue of USD 1.77 billion and earnings per share of USD 0.1621 for that quarter.

Stock price stays the live marker

Ventas was trading at EUR 75.49 at Lang & Schwarz on October 15, 2026 at 1:35 p.m. CEST. The quote is an intraday indication in Germany, while the latest primary-market context was USD 84.31 on the NYSE after the October 14 session. Ventas is a healthcare real estate investment trust whose investment case now rests on the balance between senior housing demand, operating delivery and the lower Barclays valuation.

The further course of trading is shown by the continuously updated real-time quote of Ventas stock.